UK's Hemogenyx falls on FDA clinical hold for leukemia cancer drug

Hemogenyx Pharmaceuticals

02/06/2023 13:02

** Shares of UK-based biotechnology co Hemogenyx Pharma Plc
 HEMO.L  fall as much as 34.7% to 5-month low of 1.5p 
    ** Stock is among top pct. losers on London stock exchange 
    ** Says FDA has placed its investigational new drug
application (IND) in treatment of acute myeloid leukemia on hold
    ** Co's drug candidate, HEMO-CAR-T, is designed for 
treatment of acute myeloid leukemia, which is a type of blood
and bone marrow cancer with poor survival rates    
    ** "We are confident that we will be able to address the
FDA's questions and concerns regarding the IND"- CEO
    ** As of last close, stock up 56% YTD


    

 (Reporting by Hani Kollathodi in Bengaluru)
 ((Hani.Kollathodi@thomsonreuters.com;))